A5059874383- Cancer Treatment and Pharmacology
- Circadian rhythm and melatonin
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Cancer, Stress, Anesthesia, and Immune Response
- Bladder and Urothelial Cancer Treatments
- HER2/EGFR in Cancer Research
- Immune Response and Inflammation
- Immunotherapy and Immune Responses
- Endometrial and Cervical Cancer Treatments
- Adrenal Hormones and Disorders
- Estrogen and related hormone effects
- Central Venous Catheters and Hemodialysis
- Venous Thromboembolism Diagnosis and Management
- Chemokine receptors and signaling
- Immune Cell Function and Interaction
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Chronic Lymphocytic Leukemia Research
- Cancer-related cognitive impairment studies
- Renal Diseases and Glomerulopathies
- Delphi Technique in Research
University of Milano-Bicocca
2023-2025
IFOM
2024-2025
Alessandro Manzoni Hospital
2014-2019
Ospedale Valduce
2005-2007
Associazione Italiana Di Oncologia Medica
2005
Azienda Ospedaliera Treviglio
2004
University of Cagliari
2004
Ospedale Sant'Anna
2004
Moriggia Pelascini Hospital
2004
Azienda Ospedaliera San Gerardo
1992-2004
Background: High dissemination potential and resistance to standard therapy significantly contribute high mortality associated with ovarian cancer. Cancer stem cells (CSCs) drive tumor progression, metastasis, recurrence after treatments’ failure. Here, we provide the first evidence of TIMP1 overexpression in CSCs, suggesting its role as a prognostic biomarker. Methods: Different cancer cell models were used explore link between stem-like phenotypes. Experiments included spheroid formation,...
The lack of effective screening and successful treatment contributes to high ovarian cancer mortality, making it the second most common cause gynecologic death. Development chemoresistance in up 75% patients is a poor response reduced survival. Therefore, identifying potential biomarkers for its diagnosis prognosis strong critical need. Copy number alterations are frequent cancer, relevant molecular tumor stratification patients' prognoses. In this study, array-CGH analysis was performed...
Aneuploidy is a prevalent cancer feature that occurs in many solid tumors. For example, high-grade serous ovarian shows high level of copy number alterations and genomic rearrangements. This makes variants appealing as diagnostic or prognostic biomarkers, well for their easy detection. In this study, we focused on (CN) losses shared by stem cells (CSCs) to identify chromosomal regions may be important CSC features and, turn, patients' prognosis.
5518 Background: Concomitant CT/RT is the standard treatment for LASCCHN. Induction chemotherapy followed by vs alone have not yet been compared. The feasibility of TPF has evaluated in a previous study (Int J Rad Oncol Biol Phys 2004, 59:481). Methods: Pts with inoperable stage III-IVa, PS 0–1, were randomized to [2 cycles Cisplatin 20 mg/sqm days 1–4, 5FU 800 96 hours c.i. weeks 1 and 6 during RT (66–70 Gy)] (Arm A) or 3 neoadjuvant (Docetaxel 75mg/sqm day1, 80mg/sqm 800mg/sqm c.i) same...
770 Background: Epirubicin and Vinorelbine alone or in combination are considered active ABC.The optimal duration of a chemotherapic treatment ABC patients is not know. Otherwise has limiting-dose due to its own toxicity. Methods: In this multicenter phase II study we analyzed the feasibility efficacy 6 cycles i.v. EV, followed, responder-patients, by oral VNR alone. Our preliminary results referred 26 with advanced recurrence breast cancer (21 ER +) treated first-line 75 mg/m2 die 1 25 1–8,...
<i>Objective:</i> Single-agent epirubicin was tested as primary chemotherapy treatment in patients with early breast cancer >3 cm. <i>Methods:</i> 100 women locally advanced cm were treated three cycles of single-agent at a dose 120 mg/m<sup>2</sup>. All showing tumor shrinkage to less than 3 considered candidates for conservative surgery (quadrantectomy); the remaining modified radical mastectomy carried out. Postsurgical consisted CMF except...